Your Messages Inbox
Your Article Summary
See Latest ArticlesFinding the Sweet Spot
PharmExec, 10/16/09
New drug development is risky because it involves testing potentially lethal compounds on vulnerable and frequently sick patients. The dangers are enhanced by the growing insistence of regulators that potential medicines be tested on ever larger populations based on hard–to–quantify characteristics of health status, age and gender, and in diverse geographic settings that are often unfamiliar to the sponsors.
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects
b3c newswire, 12/07/09
Allos Therapeutics Reports New Analyses of Data from Pivotal PROPEL Trial of FOLOTYN at 51st ASH Annual Meeting
Allos Therapeutics, 12/07/09
Nplate Data From MDS Studies Presented at ASH
Amgen, 12/07/09
Article Search
Sponsor